May 15th 2024
The latest news for pharma industry insiders.
Addressing Unmet Needs with LP-284 for Relapsed/Refractory Lymphomas and Solid Tumors
May 10th 2024In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, discusses how LP-284 uniquely addresses unmet needs compared to existing or emerging treatments for relapsed/refractory lymphomas and solid tumors.
Yvonne Greenstreet: Answering the Call
From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare Businesswomen’s Association Woman of the Year, is right where she wants to be: leading efforts to advance “bold ideas” in RNAi therapeutics into life-changing gains for patients.
Verona Pharma Receives $650M Investment from Oaktree Capital Management and OMERS Life Sciences
May 9th 2024Strategic financing from Oaktree Capital Management and OMERS Life Sciences is expected to support the US launch of ensifentrine, Verona’s promising chronic obstructive pulmonary disease treatment.
Assessing LP-284 with RADR for NHL and Other Targeted Cancers
May 8th 2024In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, explains which specific endpoints they'll be looking at in the Phase I trial to assess LP-284's potential efficacy and how the insights gained will be fed back into RADR®